As always some very rational thoughts Wasa, though tend to discount letting the ship sink, especially given the market space being somewhat hot right now. Perhaps there is at least 1 other option - quick survival CR (yep, will hurt) followed some time later by bringing in some synergistic / symbiotic product already in development on some sort of deal to keep the cash price down - still involves dilution but would regenerate the business. Lots of similar examples in the past !
Disregarding miracles, suggest the upside is still down the darkened tunnel someways away. Tough game for the LTH's but still of interest to treat as a new investment. GLTAH
Ann: Anagrelide Cancer Patent For Japan, page-10
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $200.6M | |||
| Open | High | Low | Value | Volume |
| 18.8¢ | 19.0¢ | 18.5¢ | $115.0K | 609.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 226209 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 791369 | 7 |
View Market Depth
| Last trade - 15.59pm 08/11/2024 (20 minute delay) ? |
| ALA (ASX) Chart |